It has been found by the FDA that some patients who have taken Sanofi-Aventis' (SNY) Multaq heart disease drug have suffered from some or the other kind of liver disease. And that is why it has put the drug in the warning category.

After the recent FDA finding, the company will have to put up a risk sign as a label on its bottles. Since Multaq got it approval in 2009, it has been prescribed at least a million times. Bottles of the drug already carry a warning that says that it can have severe complications.

No comment has been sent by the company and since the directives came, the shares of the company went down by 0.2 per cent to be at 34.35.

On Friday, the French drugmaker had said that two patients who had taken Multaq suffered from liver damage and they had to go through transplants. But, it did not mention any kind of link between the usage of drug and the health issues.

Sanofi had later on sent a letter to the US and while talking to the press, company spokesman Jean-Marc Podvin had assured that patients' safety was the priority for Sanofi.